Gain Therapeutics, Inc. (GANX:NASDAQ) closed at $1.11 on November 4, 2026, down 3.48% on the day. The stock trades 74.4% below its 52-week high of $4.34 and 0.9% above its 52-week low of $1.10. Over the past year, it lost 41.6%. Gain Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 4, 2025, GANX closed higher on 105 days (42%). Its best day was February 24, 2026 (+31.10%) and its worst was December 18, 2025 (-44.44%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 2 times.
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
Find more stocks like GANX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.